Immunotherapy has emerged as promising treatment in sarcomas, but the high variability in
terms of histology, clinical behavior and response to treatments determines a particular …

The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene
fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the …

Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be
considered as a spectrum of the same disease entity, representing one of the most common …

Genomic profiling has improved our understanding of the pathogenesis of different cancers
and led to the development of several targeted therapies, especially in epithelial tumors. In …

NTRK-rearranged spindle cell neoplasms (NTRK-RSCNs) represent an emerging group of
rare tumours defined using molecular means. To the best of our knowledge, there have …

Objective To analyze the effectiveness of the long-term (> 12 months) administration of
anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas …

Simple Summary Recently, there has been increasing interest in identifying NTRK fusions in
various tumors, as they are therapeutically targetable driver mutations. In tumor types with …

Anti-angiogenesis therapy plays a vital role in the treatment of tumors, with anlotinib as its
representative targeted drug. Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) with …

Introduction: BRAF V600E substitution predicts sensitivity of a cancer to BRAF inhibitor
therapy. The mutation is rarely found in soft-tissue sarcomas. Here we describe a case of …

Oligometastatic soft tissue sarcoma represents an intermediate state between localized and
disseminated disease. Combination A combination of surgery, radiotherapy and systemic …